You just read:

IsoRay, Inc. Announces the Launch of a Pilot Study Using Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Resectable High Risk Recurrent Head and Neck Cancer by Case Comprehensive Cancer Center

News provided by

IsoRay, Inc.

Dec 21, 2016, 08:30 ET